Expression of IL-4 in Tumors: A Safety Surrogate to Predict Cancer Survival Associated With Biologic Therapies.
J Drugs Dermatol
; 23(4): e118-e119, 2024 04 01.
Article
en En
| MEDLINE
| ID: mdl-38564398
ABSTRACT
Interleukin (IL)-4-targeted therapies have revolutionized management of inflammatory dermatoses.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Psoriasis
/
Productos Biológicos
/
Neoplasias
Idioma:
En
Revista:
J Drugs Dermatol
Asunto de la revista:
DERMATOLOGIA
Año:
2024
Tipo del documento:
Article